Triple-drug regimen lowers A1C, treatment failure in new-onset diabetes

10/8/2013 | InternalMedicineNews.com (free registration)

Patients with new-onset type 2 diabetes who had initial triple-drug treatment of metformin, exenatide and pioglitazone attained a mean A1C of 5.9% at two years, compared with 6.6% in those who received conventional stepwise treatment, a study indicated. Researchers also found the triple-drug regimen was associated with an 84% reduction in two-year treatment failure rates compared with standard therapy. The results were presented at the European Association for the Study of Diabetes meeting.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC